PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 4 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
The utility of Mucuna gigantea and other Mucuna species in the treatment of Parkinson's Disease has been evaluated due to natural levodopa content [PMID:23795319].
In-silico docking and rat models using petroleum ether, ethanolic, and aqueous extracts were used to evaluate anti-inflammatory and anti-arthritic properties [PMID:37592791].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 23795319 (2013) — Case of levodopa toxicity from ingestion of Mucuna gigantea. · Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health
- 2.PMID: 37592791 (2025) — Anti-inflammatory and Anti-arthritic Properties of Mucuna gigantea Plant Extracts: Establishing by Molecular Docking Study. · Current computer-aided drug design
- 3.PMID: 2017426 (1991) — The biochemical composition and nutritional potential of the tribal pulse, Mucuna gigantea (Willd) DC. · Plant foods for human nutrition (Dordrecht, Netherlands)
- 4.PMID: 24293686 (2012) — Effect of certain indigenous processing methods on the bioactive compounds of ten different wild type legume grains. · Journal of food science and technology